Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
US-Based Firm Has December 2021 FDA Goal Date
Executive Summary
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
You may also be interested in...
Coherus: Interchangeability ‘A Melting Ice Cube,’ Price And Supply Key
Coherus’ manufacturing scale for its Yusimry adalimumab biosimilar means it will “be able to drive the price down and to be able to provide supply guarantees,” management has insisted during a recent investor conference. “We think this will be very, very important.”
FDA To Review Pfizer’s Abrilada For Humira Interchangeability
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.
What’s Next? Five Things To Look Out For In December
As 2021 draws to a close, Coherus BioSciences awaits word on its FDA filing for biosimilar Humira, while Pfizer plots a submission for a designation for interchangeability, aiming to emulate that enjoyed by Boehringer Ingelheim’s Cyltezo. Aurobindo will also plan for the exit of popular managing director Narayanan Govindarajan.